Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis

Universitair Ziekenhuis Brussel

Status: Completed

Conditions: Nephrogenic Diabetes Insipidus

Treatments: Drug: Sevoflurane

Study type: Observational

Funder types: Other

Identifiers

NCT04939753

Sevoflu-DI-IZ

Details and patient eligibility

About

The investigators aim to retrospectively explore the electronic medical records of all patients who were admitted to the Intensive Care Unit (ICU) of the UZ Brussels in the last 10 years (March 1st 2011- March 1st 2021) and who received prolonged sedation (>24h) with sevoflurane.

Enrollment: 1,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Sevoflurane administration >24h
• 18 years and older

Exclusion criteria

• < 18 years old
• Pre-existing diabetes insipidus
• Use of drugs at risk for diabetes insipidus (including lithium, cisplatin)
• Hypercalcemia (persistently >2.75 mmol/L)
• Pituitary or acute brain surgery
• Patients requiring continuous renal replacement therapy
• Pregnancy

Trial design

1,000 participants in 1 patient group

Sevoflurane group

Description:

Patients that received sevoflurane while in ICU care.

Treatment:

Drug: Sevoflurane